Chuan-Xin Xia1, Yi-Wei Kao2,3, Lei Qin4, Ming-Chih Chen2, Ben-Chang Shia3,5,6, Szu-Yuan Wu7,8,9,10,11. 1. Guanghua School of Management, Peking University Beijing, China. 2. Graduate Institute of Business Administration, Fu Jen Catholic University Taipei, Taiwan. 3. Research Center of Big Data, College of Management, Taipei Medical University Taipei, Taiwan. 4. School of Statistics, University of International Business and Economics Beijing, China. 5. Executive Master Program of Business Administration in Biotechnology, College of Management, Taipei Medical University Taipei, Taiwan. 6. College of Management, Taipei Medical University Taipei, Taiwan. 7. Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University Taichung, Taiwan. 8. Department of Healthcare Administration, College of Medical and Health Science, Asia University Taichung, Taiwan. 9. Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital Yilan, Taiwan. 10. Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital Yilan, Taiwan. 11. Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan.
Abstract
BACKGROUND: Chronic rhinosinusitis (CRS) have infection, innate immune disorder and chronic inflammation problems which are considered as potential mechanism of tumorigenesis. To estimate cancer risk in CRS using propensity scores matching (PSM) case-control cohort study. METHODS: A nationwide retrospective case-control cohort study is conducted on claim data from National Health Insurance Research Database in Taiwan. From January 2000 to December 2005, case group included 32677 CRS patients (including 544 with surgery in case 1 group and 32133 without surgery in case 2 group), and control group included 98031 subjects without CRS which were matching by PSM method on all baseline characteristics. All subjects were followed up from January 2006 till December 2013, the risk of cancers were calculated during the period. Conditional logistic regression Analysis of Cancer Risk is used to calculate the odds ratio (OR) and 95% confidence interval (CI) for case, case 1 and case 2 compared with control group. The difference in cancer risk among case, case 1 and case 2 drew the conclusions of this paper. RESULTS: The risk of cancers in head and neck (adjusted OR: 1.53, 95% CI: 1.33-1.75), colon (adjusted OR: 1.23, 95% CI: 1.09-1.39), liver (adjusted OR: 1.24, 95% CI: 1.09-1.41), lung (adjusted OR: 1.14, 95% CI: 1-1.3), skin (adjusted OR: 1.37, 95% CI: 1.05-1.79), breast (adjusted OR: 1.17, 95% CI: 1.01-1.36), prostate (adjusted OR: 1.85, 95% CI: 1.54-2.22) and bladder (adjusted OR: 1.48, 95% CI: 1.17-1.48) were statistical significantly higher in CRS patients than non-CRS group. Compared with CRS patients without surgery, risk of cancers in head and neck, colon, liver, lung, skin, breast, and prostate were higher in CRS patients receiving surgery. CONCLUSION: Cancer risk in CRS patients is significant high than non-CRS patients, especially in head and neck, breast, lung, bladder, colorectal, liver, prostate, and skin cancers. Surgical interventions in CRS patients could not decrease cancer risk in CRS patients. AJTR
BACKGROUND:Chronic rhinosinusitis (CRS) have infection, innate immune disorder and chronic inflammation problems which are considered as potential mechanism of tumorigenesis. To estimate cancer risk in CRS using propensity scores matching (PSM) case-control cohort study. METHODS: A nationwide retrospective case-control cohort study is conducted on claim data from National Health Insurance Research Database in Taiwan. From January 2000 to December 2005, case group included 32677 CRSpatients (including 544 with surgery in case 1 group and 32133 without surgery in case 2 group), and control group included 98031 subjects without CRS which were matching by PSM method on all baseline characteristics. All subjects were followed up from January 2006 till December 2013, the risk of cancers were calculated during the period. Conditional logistic regression Analysis of Cancer Risk is used to calculate the odds ratio (OR) and 95% confidence interval (CI) for case, case 1 and case 2 compared with control group. The difference in cancer risk among case, case 1 and case 2 drew the conclusions of this paper. RESULTS: The risk of cancers in head and neck (adjusted OR: 1.53, 95% CI: 1.33-1.75), colon (adjusted OR: 1.23, 95% CI: 1.09-1.39), liver (adjusted OR: 1.24, 95% CI: 1.09-1.41), lung (adjusted OR: 1.14, 95% CI: 1-1.3), skin (adjusted OR: 1.37, 95% CI: 1.05-1.79), breast (adjusted OR: 1.17, 95% CI: 1.01-1.36), prostate (adjusted OR: 1.85, 95% CI: 1.54-2.22) and bladder (adjusted OR: 1.48, 95% CI: 1.17-1.48) were statistical significantly higher in CRSpatients than non-CRS group. Compared with CRSpatients without surgery, risk of cancers in head and neck, colon, liver, lung, skin, breast, and prostate were higher in CRSpatients receiving surgery. CONCLUSION:Cancer risk in CRSpatients is significant high than non-CRSpatients, especially in head and neck, breast, lung, bladder, colorectal, liver, prostate, and skin cancers. Surgical interventions in CRSpatients could not decrease cancer risk in CRSpatients. AJTR
Authors: Karen Head; Lee Yee Chong; Patorn Piromchai; Claire Hopkins; Carl Philpott; Anne G M Schilder; Martin J Burton Journal: Cochrane Database Syst Rev Date: 2016-04-26